Table 2.
The Comparison of Antimicrobial Susceptibility Profile Between ESBL-Producing and Non-ESBL-Producing Isolates
| Antibiotics | ESBL (+) | ESBL (-) | P-value | ||||
|---|---|---|---|---|---|---|---|
| No. Tested | %(R) | %(S) | No. Tested | %(R) | %(S) | ||
| Ampicillin | 4295 | 99.9 | 0.1 | 3418 | 71.0 | 26.6 | <0.001 |
| Cefoperazone/Sulbactam | 2433 | 6.5 | 69.2 | 2154 | 4.0 | 91.9 | <0.001 |
| Ampicillin/Sulbactam | 3762 | 69.2 | 11.7 | 2897 | 32.6 | 39.1 | <0.001 |
| Piperacillin/Tazobactam | 4295 | 1.2 | 95.3 | 3418 | 2.9 | 94.1 | <0.001 |
| Ceftazidime | 4295 | 44.9 | 52.3 | 3418 | 7.6 | 91.9 | <0.001 |
| Ceftriaxone | 4295 | 99.0 | 0.9 | 3418 | 11.7 | 88.2 | <0.001 |
| Cefepime | 4295 | 33.6 | 48.8 | 3418 | 4.9 | 94.1 | <0.001 |
| Cefoxitin | 2307 | 11.3 | 80.1 | 2028 | 12.0 | 85.3 | 0.524 |
| Aztreonam | 4170 | 66.8 | 31.7 | 3317 | 7.5 | 92.0 | <0.001 |
| Ertapenem | 4295 | 0.5 | 98.8 | 3418 | 2.2 | 97.2 | <0.001 |
| Imipenem | 4295 | 0 | 100 | 3418 | 1.0 | 98.8 | <0.001 |
| Meropenem | 2425 | 0 | 100 | 2147 | 1.3 | 98.7 | <0.001 |
| Amikacin | 4137 | 3.5 | 96 | 3313 | 1.1 | 98.5 | <0.001 |
| Gentamicin | 4070 | 51.7 | 47.2 | 3219 | 34.6 | 64.5 | <0.001 |
| Tobramycin | 3888 | 22.4 | 45 | 3022 | 7.1 | 64.7 | <0.001 |
| Ciprofloxacin | 4295 | 82.4 | 14.3 | 3418 | 49.9 | 43.8 | <0.001 |
| Levofloxacin | 4295 | 77.1 | 6.3 | 3418 | 44.5 | 23.4 | <0.001 |
| Trimethoprim/Sulfamethoxazole | 4012 | 64.4 | 35.6 | 3225 | 47.5 | 52.5 | <0.001 |
| Nitrofurantoin | 3881 | 4.0 | 83.6 | 3018 | 2.1 | 90.7 | <0.001 |
Abbreviations: ESBL (+), ESBL-producing isolates; ESBL (-), non-ESBL-producing isolates.